Former National Institutes of Health Director Elias Zerhouni has joined Danaher's board, the company said this week.
Zerhouni was appointed to fill a vacancy, the company said, adding that his initial term expires at the company's 2011 annual meeting.
Zerhouni was director of the NIH from 2002 to 2008. He currently is senior advisor at the Johns Hopkins University School of Medicine and is a senior fellow for the Bill and Melinda Gates Foundation Global Health Program.
He received his medical degree in 1975 from the University of Algiers. He completed his residency in diagnostic radiology at Johns Hopkins in 1978 and became a full professor of radiology in 1992 and a professor of biomedical engineering three years later. He became director of the Department of Radiology in 1996 and eventually served as vice dean for clinical affairs, president of the Johns Hopkins Clinical Practice Association, vice dean for research, and executive vice dean for the Johns Hopkins University School of Medicine.
Antibody therapeutic firm Oxford BioTherapeutics this week announced the appointment of Michael Moore as its non-executive chairman.
Moore has several decades of senior management experience in the biotechnology field. He was most recently the CEO of Piramed before it was acquired by Roche in 2008. Prior to that, he was chief scientific officer and research director of Xenova Group.
Oxford BioTherapeutics was formerly called Oxford Genome Sciences and develops targeted antibody medicines for oncology, based on novel targets discovered in its OGAP proteomic database.